Skip to content
10-Q

Quarterly Report

Semnur Pharmaceuticals, Inc. SMNR SMNRW

0001213900-25-077047

← back to feed
Filed
Aug 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Stock Repurchased Q2 2025 · Jun 30, 2025 $8.62M
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$183.51K
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$488.66K
Stockholders Equity Q2 2025 · Jun 30, 2025 −$11.14M
Stockholders Equity Q2 2025 · Mar 31, 2025 −$10.74M
Stockholders Equity Q2 2025 · Dec 31, 2024 −$10.42M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$9.16M
Stockholders Equity Q2 2025 · Mar 31, 2024 −$8.82M
Stockholders Equity Q2 2025 · Dec 31, 2023 −$8.28M
Current Liabilities Q2 2025 · Jun 30, 2025 $8.27M
Current Liabilities Q2 2025 · Dec 31, 2024 $7.55M
Total Liabilities Q2 2025 · Jun 30, 2025 $11.16M
Total Liabilities Q2 2025 · Dec 31, 2024 $10.43M
Current Assets Q2 2025 · Jun 30, 2025 $14.14K
Current Assets Q2 2025 · Dec 31, 2024 $16.87K
Total Assets Q2 2025 · Jun 30, 2025 $562.46K
Total Assets Q2 2025 · Dec 31, 2024 $9.04M
Net Income Q2 2025 · Jun 30, 2025 −$385.12K
Net Income Q2 2025 · Jun 30, 2025 −$579.73K
Net Income Q2 2025 · Mar 31, 2025 −$194.6K
Net Income Q2 2025 · Jun 30, 2024 $448.91K
Net Income Q2 2025 · Jun 30, 2024 $713.24K
Net Income Q2 2025 · Mar 31, 2024 $264.33K
Operating Income Q2 2025 · Jun 30, 2025 −$374.86K
Operating Income Q2 2025 · Jun 30, 2025 −$621.46K
Operating Income Q2 2025 · Jun 30, 2024 −$168.19K
Operating Income Q2 2025 · Jun 30, 2024 −$536.44K
Revenue Q2 2025 · Oct 2, 2024 $50M